The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
Publication
, Conference
Sharifi, N; Azad, A; Patel, M; Hearn, JWD; Wozniak, M; Zohren, F; Sugg, J; Haas, GP; Stenzl, A; Armstrong, AJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sharifi, N., Azad, A., Patel, M., Hearn, J. W. D., Wozniak, M., Zohren, F., … Armstrong, A. J. (2022). The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Sharifi, Nima, Arun Azad, Mona Patel, Jason W. D. Hearn, Michele Wozniak, Fabian Zohren, Jennifer Sugg, Gabriel P. Haas, Arnulf Stenzl, and Andrew J. Armstrong. “The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Sharifi N, Azad A, Patel M, Hearn JWD, Wozniak M, Zohren F, et al. The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Sharifi, Nima, et al. “The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Sharifi N, Azad A, Patel M, Hearn JWD, Wozniak M, Zohren F, Sugg J, Haas GP, Stenzl A, Armstrong AJ. The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences